Saint-André P, Baquillon G, David M
Association Franćaise des Fondations Raoul Follerau, Paris, France.
Acta Leprol. 1989;7(1):57-8.
Ribomunyl can in practice be profitably included in the range of immunostimulants, but it requires weekly injections and hence surveillance that will also enable any adverse reactions to be monitored. Its action and tolerance after polychemotherapy have still to be studied. On the basis of our experience, we feel that only isoprinosine, whose effectiveness and good tolerance we have demonstrated, can be used for self-treatment in a mass campaign.
在实际应用中，力保美达可被纳入免疫刺激剂范围内并带来益处，但它需要每周注射，因此需要进行监测，以便也能监测任何不良反应。其在多药化疗后的作用和耐受性仍有待研究。根据我们的经验，我们认为只有异丙肌苷，我们已证明其有效性和良好耐受性，可在大规模运动中用于自我治疗。
